Filing summary
Entity note: The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-Q, not a filing under the requested company name, TALPHERA, INC. This summary reflects the filing text.
Business context and reporting period
The report covers the quarter and six months ended June 30, 2015; it was filed August 3, 2015. AcelRx is a development-stage specialty pharmaceutical company focused on acute-pain therapies. It had no commercial product revenue. Its principal programs were Zalviso, a hospital patient-controlled analgesia system, and ARX-04, a single-dose sublingual sufentanil product.
Financial results and position
Amounts below are in millions of dollars except per-share data. There is no product-sales gross margin to report.
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $1.924 | $0.071 | $2.105 | $0.166 |
| Research and development | $7.310 | $7.284 | $13.616 | $11.995 |
| General and administrative | $2.735 | $5.047 | $7.256 | $8.972 |
| Operating loss | $(8.123) | $(12.260) | $(19.523) | $(20.801) |
| Net loss | $(8.896) | $(10.575) | $(18.922) | $(20.206) |
| Basic net loss per share | $(0.20) | $(0.24) | $(0.43) | $(0.47) |
- Q2 revenue included $1.438 million of U.S. Department of Defense (DoD) contract revenue and $0.486 million of Grunenthal collaboration revenue. Six-month amounts were $1.438 million and $0.667 million, respectively.
- Six-month operating cash use was $21.438 million, versus $19.943 million a year earlier. Investing activities used $0.977 million; financing activities used $1.781 million, compared with $10.729 million provided in the first half of 2014.
- Cash, cash equivalents and short-term investments were $51.2 million at June 30, 2015, down from $75.4 million at December 31, 2014. Accumulated deficit was $197.7 million.
- Outstanding Hercules debt was $23.1 million. The balance sheet reported $9.5 million current and $13.6 million long-term debt. Interest expense was $0.777 million for Q2 and $1.583 million for the first half.
- Total assets were $63.6 million; total liabilities were $30.2 million and stockholders’ equity was $33.4 million at June 30, 2015.
Changes versus prior comparable periods
- Revenue increased substantially, primarily because the DoD began reimbursing qualifying ARX-04 development costs under a contract entered in May 2015, worth up to $17 million.
- Q2 operating loss narrowed, mainly as G&A expense fell 46% to $2.735 million; six-month G&A fell 19%. The company attributed the reduction largely to lower market research and pre-commercialization activity after its cost-reduction plan.
- R&D was nearly flat in Q2 and up 14% for the half year. Lower Zalviso spending was offset by higher ARX-04 clinical development and overhead costs.
- Six-month net loss narrowed, but reported results included significant non-cash warrant revaluation effects. The PIPE warrant liability fell to $0.916 million from $5.577 million at year-end, generating a $2.117 million six-month gain; the liability’s fair-value movement can make earnings volatile.
- Cash declined by $24.2 million during the first half. The company made $2.240 million of debt payments and did not draw new debt in that period.
Outlook, commentary and material risks
- Zalviso—U.S. regulatory uncertainty: The FDA issued a Complete Response Letter in July 2014. In March 2015 it said an additional clinical trial was needed to assess inadvertent dispensing and dispensing failures. A General Advice meeting was scheduled for early September 2015. The company had not resubmitted the NDA and said the scope and cost of further work were uncertain.
- ARX-04: The pivotal Phase 3 SAP301 study was fully enrolled, with top-line results expected early in Q4 2015. The company planned to start an additional open-label emergency-room safety study in Q3 2015. Management said DoD support, together with company resources, was expected to fund the Phase 3 program through an intended 2016 NDA submission.
- Runway and financing: Management expected existing resources to cover operations through at least the first half of 2016, excluding possible Grunenthal milestones, additional financing or partnerships. It cautioned that a large Zalviso trial could exceed available resources and require additional capital. The forecast is subject to uncertainty.
- Debt availability: The potential third Hercules tranche of up to $15 million depended on FDA approval of Zalviso by August 1, 2015. Approval was not obtained by that date, so the company had no access to the tranche. Debt is secured by substantially all assets other than intellectual property; scheduled maturity is October 1, 2017, with a $1.7 million final payment.
- European Zalviso developments after quarter-end: On July 23, 2015, the EMA’s CHMP issued a positive opinion recommending authorization; the European Commission had final authority, with a decision anticipated in late September or early October. July amendments to the Grunenthal agreements increased specified supply pricing, reduced sales-target milestones from $171.5 million to $166.0 million, and provided for additional near-term development costs paid by Grunenthal. Approval and commercial sales remained uncertain.
- Restructuring and leadership: A March cost-reduction plan eliminated 19 positions, about 36% of headcount. AcelRx reported 33 full-time employees at June 30. Howard B. Rosen was serving as interim CEO.
- Other risks and contingencies: A securities class action alleging violations related to Zalviso statements sought unspecified damages; the company intended to defend itself. Other key risks include reliance on third-party manufacturing and limited suppliers, controlled-substance regulation, clinical and regulatory setbacks, need for future financing, commercial acceptance and reimbursement, and potential dilution.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing names AcelRx Pharmaceuticals, Inc., although the request names TALPHERA, INC.
- Check the outcome of the September 2015 FDA meeting, any additional Zalviso study requirements, expected cost and timing, and the status of any NDA resubmission.
- Verify SAP301 results and the progress, enrollment and funding of the planned ARX-04 safety study and NDA program.
- Track European Commission authorization, Grunenthal milestone eligibility, and whether the amended commercial and supply terms lead to revenue.
- Assess cash use against the stated first-half-2016 runway, DoD reimbursements, available financing, debt service and the lost Hercules tranche.
- Review subsequent developments in the securities litigation and any material changes to manufacturing, supply or regulatory risks.